M. Vitali (Milano, IT)
Presenter Of 1 Presentation
P164 - Clinical and Functional Evaluation of ADSC vs BMAC in the Treatment of Knee Osteoarthritis at 6 Months Follow Up
Abstract
Purpose
The aim of this study is to compare the efficacy of a single Adipose Derived Stem Cells infiltration (ADSC) versus a single Bone Marrow Aspirate Concentrate (BMAC) infiltration in the treatment of knee OA.
Methods and Materials
30 patients suffering from knee OA were evaluated, 15 treated with a single BMAC infiltration and 15 with a single ADSC infiltration. These patients were selected after clinical and radiological examination. Patients were evaluated according to three parameters VAS, WOMAC score and Range of Motion (ROM), which were measured: pre-treatment; 1 month after treatment and then again after 3- and 6-months using T-test statistical analysis. The exclusion criteria were: Kellgren Lawrence grade IV, knee instability, meniscal pathology, severe malalignment and inflammatory arthritis.
Results
In both groups we observed a statistically significant reduction of VAS and WOMAC scores, as well as improvements in ROM, at the 6 months follow up. The comparison between the two groups did not give statistically significant differences in results for the VAS and WOMAC scores at the 6 months follow up with p values equal to 0.781 and 0.679, respectively. Instead regarding the ROM, specifically the joint flexion, a statistically significant reduction can be observed at 1 month and at 3 months follow-up (respectively p value 0.014 and p value 0.003) after BMAC infiltration. No side effects were observed in both groups.
Conclusion
Both ADSC and BMAC therapies are safe and valid approaches in the treatment of knee osteoarthritis; as they are both effective in significantly reducing the symptoms as well as improving the ROM. Prospective studies will be focused on evaluating a tailored approach for each patient in the selective use of BMAC or ADSC according to personal biological parameters such as age, osteoarthritis stage and hematological status.
Presenter Of 1 Presentation
P164 - Clinical and Functional Evaluation of ADSC vs BMAC in the Treatment of Knee Osteoarthritis at 6 Months Follow Up
Abstract
Purpose
The aim of this study is to compare the efficacy of a single Adipose Derived Stem Cells infiltration (ADSC) versus a single Bone Marrow Aspirate Concentrate (BMAC) infiltration in the treatment of knee OA.
Methods and Materials
30 patients suffering from knee OA were evaluated, 15 treated with a single BMAC infiltration and 15 with a single ADSC infiltration. These patients were selected after clinical and radiological examination. Patients were evaluated according to three parameters VAS, WOMAC score and Range of Motion (ROM), which were measured: pre-treatment; 1 month after treatment and then again after 3- and 6-months using T-test statistical analysis. The exclusion criteria were: Kellgren Lawrence grade IV, knee instability, meniscal pathology, severe malalignment and inflammatory arthritis.
Results
In both groups we observed a statistically significant reduction of VAS and WOMAC scores, as well as improvements in ROM, at the 6 months follow up. The comparison between the two groups did not give statistically significant differences in results for the VAS and WOMAC scores at the 6 months follow up with p values equal to 0.781 and 0.679, respectively. Instead regarding the ROM, specifically the joint flexion, a statistically significant reduction can be observed at 1 month and at 3 months follow-up (respectively p value 0.014 and p value 0.003) after BMAC infiltration. No side effects were observed in both groups.
Conclusion
Both ADSC and BMAC therapies are safe and valid approaches in the treatment of knee osteoarthritis; as they are both effective in significantly reducing the symptoms as well as improving the ROM. Prospective studies will be focused on evaluating a tailored approach for each patient in the selective use of BMAC or ADSC according to personal biological parameters such as age, osteoarthritis stage and hematological status.